Vector Biomed Capabilities Update September 2026: Viral Vectors

Improved lentiviral vector (LV) production and resulting higher titer provides significant clinical and commercial benefits for any LV-mediated advanced therapy. Likewise, lower product impurities and increased potency are always welcome improvements. Discover an LV platform engineered to deliver both: increased titer and improved product quality. Vector BioMed's LENTIVERSE™ provides a high-titer toolbox for LV, backed by proprietary technology and expert design for a streamlined approach. Next-generation LV-based products require higher yield with lower impurities, and leading targeted vector technologies, like efficient vector membrane engineering, to activate and stimulate T cell expansion. Supporting in vivo CAR-T clinical development starts with the same pragmatic foundation as other LV-based therapies, i.e., rapid optimization, enhanced function, cost-effective manufacturing, and a path to commercial.